Multicentre evaluation of targeted and systematic biopsies using magnetic resonance and ultrasound image-fusion guided transperineal prostate biopsy in patients with a previous negative biopsy

• Verfasst von: Hansen, Nienke Lynn [VerfasserIn]
• Verfasst von: Kesch, Claudia [VerfasserIn]
• Verfasst von: Radtke, Jan Philipp [VerfasserIn]
• Verfasst von: Bonekamp, David [VerfasserIn]
• Verfasst von: Schlemmer, Heinz-Peter [VerfasserIn]
• Verfasst von: Wieczorek, Kathrin [VerfasserIn]
• Verfasst von: Hohenfellner, Markus [VerfasserIn]
• Verfasst von: Hadaschik, Boris [VerfasserIn]
• Titel: Multicentre evaluation of targeted and systematic biopsies using magnetic resonance and ultrasound image-fusion guided transperineal prostate biopsy in patients with a previous negative biopsy
• Verf.angabe: Nienke L. Hansen, Claudia Kesch, Tristan Barrett, Brendan Koo, Jan P. Radtke, David Bonekamp, Heinz-Peter Schlemmer, Anne Y. Warren, Kathrin Wieczorek, Markus Hohenfellner, Christof Kastner, Boris Hadaschik
• Jahr: 2017
• Jahr des Originals: 2016
• Umfang: 8 S.
• Fussnoten: Published online: 10 November 2016 ; Gesehen am 26.07.2018
• Titel Quelle: Enthalten in: BJU international
• Ort Quelle: Oxford : Wiley-Blackwell, 1999
• Jahr Quelle: 2017
• Band/Heft Quelle: 120(2017), 5, Seite 631-638
• ISSN Quelle: 1464-410X
• DOI: doi:10.1111/bju.13711
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: #PCSM
• Sach-SW: #ProstateCancer
• Sach-SW: image fusion
• Sach-SW: magnetic resonance imaging
• Sach-SW: prostate biopsy
• Sach-SW: prostate cancer
• Sach-SW: prostate-specific antigen density
• Sach-SW: transperineal biopsy
• K10plus-PPN: 1577968042

Abstract

Objectives To evaluate the detection rates of targeted and systematic biopsies in magnetic resonance imaging (MRI) and ultrasound (US) image-fusion transperineal prostate biopsy for patients with previous benign transrectal biopsies in two high-volume centres. Patients and Methods A two centre prospective outcome study of 487 patients with previous benign biopsies that underwent transperineal MRI/US fusion-guided targeted and systematic saturation biopsy from 2012 to 2015. Multiparametric MRI (mpMRI) was reported according to Prostate Imaging Reporting and Data System (PI-RADS) Version 1. Detection of Gleason score 7-10 prostate cancer on biopsy was the primary outcome. Positive (PPV) and negative (NPV) predictive values including 95% confidence intervals (95% CIs) were calculated. Detection rates of targeted and systematic biopsies were compared using McNemar's test. Results The median (interquartile range) PSA level was 9.0 (6.7-13.4) ng/mL. PI-RADS 3-5 mpMRI lesions were reported in 343 (70%) patients and Gleason score 7-10 prostate cancer was detected in 149 (31%). The PPV (95% CI) for detecting Gleason score 7-10 prostate cancer was 0.20 (±0.07) for PI-RADS 3, 0.32 (±0.09) for PI-RADS 4, and 0.70 (±0.08) for PI-RADS 5. The NPV (95% CI) of PI-RADS 1-2 was 0.92 (±0.04) for Gleason score 7-10 and 0.99 (±0.02) for Gleason score ≥4 + 3 cancer. Systematic biopsies alone found 125/138 (91%) Gleason score 7-10 cancers. In patients with suspicious lesions (PI-RADS 4-5) on mpMRI, systematic biopsies would not have detected 12/113 significant prostate cancers (11%), while targeted biopsies alone would have failed to diagnose 10/113 (9%). In equivocal lesions (PI-RADS 3), targeted biopsy alone would not have diagnosed 14/25 (56%) of Gleason score 7-10 cancers, whereas systematic biopsies alone would have missed 1/25 (4%). Combination with PSA density improved the area under the curve of PI-RADS from 0.822 to 0.846. Conclusion In patients with high probability mpMRI lesions, the highest detection rates of Gleason score 7-10 cancer still required combined targeted and systematic MRI/US image-fusion; however, systematic biopsy alone may be sufficient in patients with equivocal lesions. Repeated prostate biopsies may not be needed at all for patients with a low PSA density and a negative mpMRI read by experienced radiologists.